United States · Funded startup

Who invested in Meitheal Pharmaceuticals

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$35Mraised across 1 round since 2023, from 1 source

Latest round
Debt, $35MAug 2023
Investors
1
See who backed them

The rounds

  1. Aug 2023
    Debt$35M

    Source recorded

Founders and team

From Meitheal Pharmaceuticals's own website: 6 on the team.

  • Tom SheaChief Executive Officer
  • Dr. Lonnie D. Brent PharmDSenior Vice President of Medical Affairs
  • John SpilmanVice President of Corporate Strategy
  • Lidia GantoiSenior Vice President of Finance
  • Paul TanakaSenior Vice President of Supply Chain
  • Shakuntala MaharajSenior Vice President of Quality

Everyone who backed them

JP MorganInvestment bank1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Meitheal Pharmaceuticals

Who invested in Meitheal Pharmaceuticals?

Meitheal Pharmaceuticals's investors include JP Morgan.

How much has Meitheal Pharmaceuticals raised?

Meitheal Pharmaceuticals has raised $35M across 1 round since 2023.

When did Meitheal Pharmaceuticals last raise?

Meitheal Pharmaceuticals's most recent round was a Debt of $35M in Aug 2023.

What was Meitheal Pharmaceuticals's biggest round?

Its most recent round, $35M in Aug 2023, is also its largest on record.

Who backed Meitheal Pharmaceuticals first?

Meitheal Pharmaceuticals's first round on record, in Aug 2023, was backed by JP Morgan.

What stage is Meitheal Pharmaceuticals at?

Meitheal Pharmaceuticals's latest named round is a Debt, in Aug 2023.

Where is Meitheal Pharmaceuticals based?

Meitheal Pharmaceuticals is based in the United States.

Companies like Meitheal Pharmaceuticals

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.